UBS Group’s Aclaris Therapeutics ACRS Stock Holding History
Bought
Maintained
Sold
Other funds holding ACRS
BCM
UBS Group's ACRS Position: Q3 2026 in Review
UBS Group increased its Aclaris Therapeutics (ACRS) stake by 89% in Q3 2026, buying an estimated $1.3M and bringing the position to 484,501 shares worth $2.55M. The position accounts for ﹤0.01% of the portfolio, ranked #4800.
UBS Group first reported a position in ACRS in Q4 2015 and has held it in 44 quarters since. The position peaked at $9.7M in Q4 2018. 167 funds tracked by Wall St. Rank hold ACRS as of Q3 2026.
- UBS Group held 484,501 shares of Aclaris Therapeutics worth $2.55M as of Q3 2026.
- UBS Group bought 227,500 Aclaris Therapeutics shares in Q3 2026, an estimated $1.3M.
- Aclaris Therapeutics made up ﹤0.01% of UBS Group's portfolio in Q3 2026, its #4800 holding.
- UBS Group first reported a position in Aclaris Therapeutics in Q4 2015 and has held it in 44 quarters since.
- UBS Group's Aclaris Therapeutics position peaked at $9.7M in Q4 2018.
- 167 funds tracked by Wall St. Rank held Aclaris Therapeutics as of Q3 2026.
Based on UBS Group's 13F filing for Q3 2026, filed 10 Nov 2026.